Hemerion team has been developing its technology since 2010 within the frame of scientific and clinical research teams located in Lille. Our endeavours led to a successful clinical validation in 2021.
Hemerion has completed a Series A financing round totaling more than €6.5 million, involving investment funds, public funding, business angels, and more than 260 private investors participating in a European crowdfunding campaign.
Hemerion obtains ISO 13485:2016 certification for its quality management system for photonic medical devices from the British Standard Institute (BSI).
Hemerion Therapeutics obtains “Fast Track” status from the FDA for its combined Pentalafen® / Heliance® therapy in the treatment of glioblastoma.
Hemerion wins the INPI 2024 Trophy in the “ Research Partnership” category. Created in 1991, this prestigious competition, organized by the French Institute of Industrial Property (INPI), recognizes exemplary companies in terms of intellectual property strategy.
A first patient is treated in Pittsburgh, Pennsylvania as part of the new clinical trial sponsored by Hemerion. The study (HTX-GBM-01) is designed to confirm the safety and feasibility of the Pentalafen® / Heliance® combination therapy in the treatment of glioblastoma : a first in the USA.
Read the press release
The FDA authorization enables Hemerion to commence a Phase 1/2 clinical study at University of Pittsburgh Medical Center by Q4 2023 to evaluate the upgraded Pentalafen® / Heliance® platform.
Read the press release
Granted as part of Bpifrance’s Deeptech Plan, this financing allows Hemerion to accelerate the implementation of a new clinical trial.
One year after the first round of funding, Hemerion’s new €3.55 million financing will accelerate the implementation of international clinical trials for the treatment of glioblastoma.
Hemerion and Mount Sinai Health System (NYC) are collaborating to launch an ambitious clinical trial in 2022. This project has won the “Best Collaboration in the MedTech and Digital Health” award of the Galien Medstartup Prize: an international recognition that perfectly kickstarts the Hemerion development in the USA.
Ground breaking preliminary results from the clinical study are published in the Journal of Neuro-Oncology. The Hemerion’s technology covered the 2018’s May issue.
In the USA, the Hemerion’s technology becomes granted Orphan Drug Designation by the FDA.
Hemerion Therapeutics is founded by the scientists and inventors of the technology, among them M. Vermandel, C. Dupont, N. Reyns, S. Mordon and M. Andraud gather deep scientific how-know and entrepreneurship skills to lead the company. In the mean time, Hemerion is awarded the French Tech Label that recognizes high potential start-up companies.
The Hemerion technology is demonstrated by Pr. N. Reyns at an international neurosurgery meeting in Cambridge – Boston (MA, USA) and in New-York (NY, USA) during Fluorescence-Guided Surgery Brain Tumor Symposiums hosted at The Icahn School of Medicine at Mount Sinai by Pr. C. G. Hadjipanayis.
The Hemerion drug-device combination product is presented during the plenary session of annual congress of the European Association of the Neurosurgery Societies in Brussels (Be). First usability endpoints successfully collected during the Phase I INDYGO are reported to the European’s neurosurgeons community.
The use of Hemerion technology for the first time in the operating room, as part of a clinical trial, is detailed by the international magazine.
The enrollment phase of the clinical trial INDYGO is successfully completed, after only one year. During this study sponsored by the University Hospital of Lille (France) and with Pr. N. Reyns as the Principal Investigator, 10 patients included from may 2017 to June 2018 have been treated with the Hemerion’s technology.
M. Vermandel becomes the first ever non-US resident of being the recipient of the ASLMS research grant (American Society of Lasers in Surgery and Medicine) for his work on drugs and laser technologies combination. ASLMS was founded in 1980 and is the world’s largest professional organization dedicated to the field of medical laser.
